MedTrace Logo

Evaluation of the Safety and Efficacy of Autologous COVID-19 Antigen Specific T Cell in Prolonged SARS-CoV-2 Patients

NCT07690943 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2026-07-08

No results posted yet for this study

Summary

The goal of this clinical study is to evaluate the safety and efficacy of autologous COVID-19 antigen specific T cell (LB-DTK-COV19) treatment in prolonged SARS-CoV-2 infected patients. The main questions it aims to answer are:

* What adverse events occur after the infusion of LB-DTK-COV19?
* Is there a clinically significant improvement in clinical symptoms within 4 weeks after the infusion?
* Is there a clinically significant reduction in SARS-CoV-2 viral load within 4 weeks after the infusion?

The patients will:

* Receive a single infusion of LB-DTK-COV19 either intravenously or using central venous catheter during the baseline visit at a dose of 1x10\^7/m\^2.
* Receive a second infusion of LB-DTK-COV19 either intravenously or using central venous catheter at the same dose 14 days after the first infusion.
* Attend follow-up visits at the clinic for 6 months after the first infusion.

Conditions

  • COVID-19
  • COVID-19 (SARS-CoV-2 Infection)

Interventions

BIOLOGICAL

LB-DTK-COV19

\- LB-DTK-COV19 is an autologous SARS-CoV-2-specific T cell therapy product derived from a patient and is stored frozen in a colorless, transparent freeze-dried vial until thawed into liquid before administration.

Sponsors & Collaborators

  • LucasBio

    lead INDUSTRY

Principal Investigators

  • Rae Seok Lee, MD-PhD · Department of Infectious Disease, The Catholic University of Korea Seoul St.Mary's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-08
Primary Completion
2024-05-31
Completion
2025-01-22

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07690943 on ClinicalTrials.gov